India's Pharma Opps Hampered by Bureaucracy, Policy
A recent report from the Business Monitor outlines India's strong commercial opportunities for pharmaceutical companies...
A recent report from the Business Monitor outlines India's strong commercial opportunities for pharmaceutical companies, but government issues are increasingly making the country less attractive on many subsectors of pharma, including the regulation of clinical trials.
The Business Monitor offers a risk/reward rating for countries, and India scored a 51.8 out of a possible 100, which is below the regional average for most indicators under industry and country risks. In addition, India ranked 10th behind New Zealand out of the 19 key markets in the Asia-Pacific.
The full release can be read here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
